Avadel Pharmaceuticals plc

Symbol: AVDL

NASDAQ

15.83

USD

Market price today

  • -9.3848

    P/E Ratio

  • -0.0457

    PEG Ratio

  • 1.60B

    MRK Cap

  • 0.00%

    DIV Yield

Avadel Pharmaceuticals plc (AVDL) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.95%

Operating Profit Margin

-4.93%

Net Profit Margin

-5.73%

Return on Assets

-0.61%

Return on Equity

-2.12%

Return on Capital Employed

-0.61%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Gregory J. Divis Jr.
Full-time employees:154
City:Dublin
Address:10 Earlsfort Terrace
IPO:1996-06-07
CIK:0001012477

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

General Outlook

When we look at how much money they make before expenses, they keep 0.949% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -4.930%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -5.732%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.614% return, is a testament to Avadel Pharmaceuticals plc's adeptness in optimizing resource deployment. Avadel Pharmaceuticals plc's utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -2.116%. Furthermore, the proficiency of Avadel Pharmaceuticals plc in capital utilization is underscored by a remarkable -0.615% return on capital employed.

Stock Prices

Avadel Pharmaceuticals plc's stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $19.04, while its low point bottomed out at $18.23. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Avadel Pharmaceuticals plc's stock market.

Liquidity Ratios

Analyzing AVDL liquidity ratios reveals its financial health of the firm. The current ratio of 364.14% gauges short-term asset coverage for liabilities. The quick ratio (321.63%) assesses immediate liquidity, while the cash ratio (84.57%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio364.14%
Quick Ratio321.63%
Cash Ratio84.57%

Profitability Ratios

AVDL profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -574.96% underscores its earnings before tax deductions. The effective tax rate stands at 0.31%, revealing its tax efficiency. The net income per EBT, 99.69%, and the EBT per EBIT, 116.63%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -492.97%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-574.96%
Effective Tax Rate0.31%
Net Income per EBT99.69%
EBT per EBIT116.63%
EBIT per Revenue-492.97%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 3.64, it details the span from stock purchase to revenue. The 3 days it takes to settle debts showcases its creditor relations. Meanwhile, a 1 cash conversion cycle and 208.29% receivables turnover rate reflect its cash flow efficiency and credit management, respectively.

cards.indicatorcards.value
Days of Sales Outstanding322
Days of Inventory Outstanding2642
Operating Cycle2817.29
Days of Payables Outstanding2910
Cash Conversion Cycle-93
Receivables Turnover2.08
Payables Turnover0.13
Inventory Turnover0.14
Fixed Asset Turnover8.80
Asset Turnover0.11

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -1.35, and free cash flow per share, -1.35, depict cash generation on a per-share basis. The cash per share value, 1.11, showcases liquidity position. Lastly, the operating cash flow sales ratio, -4.60, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-1.35
Free Cash Flow per Share-1.35
Cash per Share1.11
Operating Cash Flow Sales Ratio-4.60
Free Cash Flow to Operating Cash Flow Ratio1.00
Cash Flow Coverage Ratio-3.81
Short Term Coverage Ratio-137.59

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 12.90%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.38, we discern the balance between debt and equity financing. The long-term debt to capitalization, 27.19%, and total debt to capitalization, 27.75%, ratios shed light on its capital structure. An interest coverage of -13.94 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio12.90%
Debt Equity Ratio0.38
Long Term Debt to Capitalization27.19%
Total Debt to Capitalization27.75%
Interest Coverage-13.94
Cash Flow to Debt Ratio-3.81
Company Equity Multiplier2.98

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.35, provides a glimpse into top-line earnings distributed across each share. Net income per share, -2.00, reflects the portion of profit attributed to each share. The book value per share, 1.09, represents the net asset value distributed per share, while the tangible book value per share, 0.88, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.35
Net Income Per Share-2.00
Book Value Per Share1.09
Tangible Book Value Per Share0.88
Shareholders Equity Per Share1.09
Interest Debt Per Share0.54

Growth Ratios

EBIT growth, -39.86%, and operating income growth, -39.86%, offer insights into operational profitability progression. The net income growth, -16.59%, showcases bottom-line expansion, and the EPS growth, 12.66%, measures the growth in earnings per share.

cards.indicatorcards.value
Gross Profit Growth1797.99%
EBIT Growth-39.86%
Operating Income Growth-39.86%
Net Income Growth-16.59%
EPS Growth12.66%
EPS Diluted Growth12.66%
Weighted Average Shares Growth33.41%
Weighted Average Shares Diluted Growth33.41%
Operating Cash Flow Growth-88.99%
Free Cash Flow Growth-87.09%
10-Year Revenue Growth per Share-60.50%
5-Year Revenue Growth per Share-87.39%
3-Year Revenue Growth per Share-17.24%
10-Year Operating CF Growth per Share-103.71%
5-Year Operating CF Growth per Share25.22%
3-Year Operating CF Growth per Share-80.22%
10-Year Net Income Growth per Share-18.36%
5-Year Net Income Growth per Share21.71%
3-Year Net Income Growth per Share-1607.46%
10-Year Shareholders Equity Growth per Share392.40%
5-Year Shareholders Equity Growth per Share1369.31%
3-Year Shareholders Equity Growth per Share-64.26%
Receivables Growth497.20%
Asset Growth96.65%
Book Value per Share Growth411.02%
Debt Growth-72.99%
R&D Expense Growth-35.94%
SGA Expenses Growth101.22%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 1,136,273,880, captures the company's total value, considering both debt and equity. Income quality, 0.83, assesses the reliability of reported earnings.

cards.indicatorcards.value
Enterprise Value1,136,273,880
Income Quality0.83
Research and Development to Revenue47.42%
Intangibles to Total Assets6.45%
Stock-Based Compensation to Revenue56.54%
Graham Number7.02
Return on Tangible Assets-65.61%
Graham Net Net-0.66
Working Capital97,347,000
Tangible Asset Value70,902,999
Net Current Asset Value-39,185,000
Average Receivables7,836,500
Average Payables9,661,500
Average Inventory5,190,000
Days Sales Outstanding175
Days Payables Outstanding1598
Days of Inventory On Hand1450
ROIC-113.16%
ROE-1.83%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 17.14, and the price to book ratio, 17.14, reflect the market's valuation relative to the company's book value. The price to sales ratio, 57.35, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -12.48, and price to operating cash flows, -11.70, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio17.14
Price to Book Ratio17.14
Price to Sales Ratio57.35
Price Cash Flow Ratio-11.70
Price Earnings to Growth Ratio-0.05
Enterprise Value Multiple-11.75
Price Fair Value17.14
Price to Operating Cash Flow Ratio-11.70
Price to Free Cash Flows Ratio-12.48
Price to Tangible Book Ratio12.90
Enterprise Value to Sales40.63
Enterprise Value Over EBITDA-8.35
EV to Operating Cash Flow-8.55
Earnings Yield-14.16%
Free Cash Flow Yield-11.74%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Avadel Pharmaceuticals plc (AVDL) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -9.385 in 2024.

What is the ticker symbol of Avadel Pharmaceuticals plc stock?

The ticker symbol of Avadel Pharmaceuticals plc stock is AVDL.

What is company IPO date?

IPO date of Avadel Pharmaceuticals plc is 1996-06-07.

What is company current share price?

Current share price is 15.830 USD.

What is stock market cap today?

The market cap of stock today is 1603742350.000.

What is PEG ratio in 2024?

The current -0.046 is -0.046 in 2024.

What is the number of employees in 2024?

In 2024 the company has 154.